Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

Add GALT Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 8/28/2016 10:46:55 AM - Followers: 47 - Board type: Free - Posts Today: 1

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:




Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.




Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
GALT News: Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial 08/25/2016 08:00:00 AM
GALT News: Current Report Filing (8-k) 08/25/2016 07:52:16 AM
GALT News: Securities Registration Statement (simplified Form) (s-3) 08/15/2016 05:03:21 PM
GALT News: Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update 08/09/2016 08:00:00 AM
GALT News: Current Report Filing (8-k) 08/09/2016 07:51:38 AM
#2220   Good point. Could still be very beneficial even gss2003 08/28/16 10:46:55 AM
#2219   You do not need results to be spectacular. staccani 08/27/16 01:48:33 PM
#2218   Results are encouraging for a trial on a rickyricks 08/27/16 01:44:28 PM
#2217   The PR is encouraging in areas, but it's gss2003 08/27/16 11:50:32 AM
#2216   Well, there IS a reason Clinical Trials are Adi2 08/27/16 08:51:23 AM
#2215   I'd Take anytime a reduction of liver fibrosis staccani 08/27/16 05:40:59 AM
#2214   So, basically no additional response on P. from Adi2 08/27/16 04:49:05 AM
#2213   1 month and half from nash fibrosis and staccani 08/10/16 12:23:06 PM
#2212   If the share price gets somewhere north of thefamilyman 08/09/16 12:23:34 PM
#2211   GALT burn rate was down in latest quarter, biotech2010 08/09/16 09:14:41 AM
#2210   I added today as well. This was Pete144 08/02/16 01:54:22 AM
#2209   Not sure what is moving GALT but we mjw007 08/01/16 03:39:13 PM
#2208   Very powerful move today. Someone getting a hint Adi2 08/01/16 03:28:28 PM
#2207   From Lung Disease News yesterday: IRAHopeful 07/12/16 12:18:57 PM
#2206   You will find others who agree with you. zest 06/28/16 02:45:54 PM
#2205   Just bought in for a few. Hoping gucci-67 06/28/16 10:56:02 AM
#2204   traber is trailer park trash... oldsport 06/28/16 10:02:45 AM
#2203   Somebody mis-typed $1.25??? IRAHopeful 06/27/16 05:12:01 PM
#2202   IDK but I hope that good news has thefamilyman 06/24/16 10:40:32 PM
#2201   GALT closing spike, $1.55 at 4PM on 18,058 shares biotech2010 06/24/16 04:30:48 PM
#2198   Because money won't last that far. All rests Adi2 06/22/16 01:55:11 PM
#2197   I just realized something else. The primary NASH thefamilyman 06/22/16 07:26:07 AM
#2196   Or they worry the company winds up if Adi2 06/21/16 11:26:11 PM
#2195   After they canned Czzir, I started buying again. thefamilyman 06/20/16 11:16:10 PM
#2194   Dunno. Sounds a little strange. Could it be Darwinian 06/20/16 10:59:31 PM
#2193   I don't like it. These two are insiders. thefamilyman 06/20/16 09:16:51 PM
#2192   I looked a the presentation on the website Inoviorulez 06/13/16 08:26:30 PM
#2191   If, as zest advises, "what really matters is JERZYATP1 06/09/16 08:01:27 PM
#2190   I was referring to the much higher concentration biotech2010 06/09/16 09:17:56 AM
#2189   Doesn't matter what you say, what really zest 06/09/16 01:44:16 AM
#2188   Regarding post#2186, in any case the result for JERZYATP1 06/08/16 10:41:11 PM
#2187   Not sure what you mean biotech2010 when you Pete144 06/08/16 05:22:06 PM
#2186   Psoriasis before and after photos posted by GALT biotech2010 06/08/16 08:58:13 AM
#2185   This is all really interesting, you have done biotech2010 06/01/16 01:27:19 PM
#2184   In a previous post (#2175) I cited four JERZYATP1 05/31/16 03:45:19 PM
#2183   Nothing of what you said matters. The only BelizeBeachTrader 05/30/16 11:31:45 AM
#2182   If you took 5 minutes to read the biotech2010 05/30/16 11:03:52 AM
#2181   There are no ideas that are relevant about biotech2010 05/30/16 11:02:22 AM
#2180   It was in the 10K, nothing new: biotech2010 05/30/16 11:01:12 AM
#2179   It amazes me that GALT continues to exist zest 05/29/16 10:41:21 PM
#2178   No. I'd be really interested to hear ideas. Darwinian 05/29/16 01:31:07 PM
#2177   Anybody got an idea as to the kind thefamilyman 05/27/16 01:38:47 PM
#2176   New SEC filing. Very interesting... thefamilyman 05/27/16 01:24:02 PM
#2175   In previous posts (sparse) I have implied that JERZYATP1 05/25/16 05:22:29 PM
#2174   That's an interesting perspective on where the drug biotech2010 05/23/16 03:13:23 PM
#2173   Thanks for referencing the article in -- JERZYATP1 05/20/16 10:03:46 PM
#2172   Best article about GALT I've ever read: biotech2010 05/20/16 10:14:43 AM
#2171   The PASI of 75% decline was not reached BelizeBeachTrader 05/17/16 08:43:16 PM
#2170   Only 0.07 up???? Coolec78 05/17/16 12:32:27 PM
#2169   Notes from the conference call: biotech2010 05/17/16 09:38:21 AM